Literature DB >> 9814592

CD40 ligand and autoantigen are involved in the pathogenesis of low-grade B-cell lymphomas of mucosa-associated lymphoid tissue.

A Greiner1, C Knörr, Y Qin, A Schultz, A Marx, R A Kroczek, H K Müller-Hermelink.   

Abstract

Low-grade MALT-type lymphomas are malignancies of mucosal marginal-zone B cells and preceded by reactive inflammatory lymphoid tissue. Experimental observations suggest that antigen and CD40 Ligand act during cognate T/B cell interaction and are crucial for germinal center B-cell maturation generating marginal-zone B cells. To investigate the mechanisms underlying the development of extranodal MALT-type lymphomas, the immunoglobulin receptor was sequenced and analyzed for antigen specificity using heterohybridoma technology. Furthermore, CD40 ligand expression was evaluated by immunohistochemistry and by semiquantitative RT-PCR, and ligand binding to the CD40 of tumor B cells was studied using the CD40 system. Hypermutations were found in low-grade lymphomas throughout CDR1-CDR3 suggestive of positive selection through their antigen receptor. Different VH families were used and more than 69% of tumor immunoglobulins bound different mucosal antigens. CD40L expression was found in the tumor marginal zone in substantial amounts. The in vitro proliferation response of all low-grade MALT-type lymphomas was dependent on anti-CD40-mediated signals and cytokines. Our data provide evidence that autoantigen as well as the CD40L expressed by activated nonneoplastic T cells may drive the evolution of low-grade MALT-type lymphomas either directly or by paracrine mechanisms and that antigen may contribute to lymphoma pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814592      PMCID: PMC2276023          DOI: 10.1155/1998/18679

Source DB:  PubMed          Journal:  Dev Immunol        ISSN: 1026-7905


  7 in total

1.  Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo.

Authors:  C Knörr; C Amrehn; H Seeberger; A Rosenwald; S Stilgenbauer; G Ott; H K Müller Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation.

Authors:  Elizabeth F Redente; David M Higgins; Lori D Dwyer-Nield; Ian M Orme; Mercedes Gonzalez-Juarrero; Alvin M Malkinson
Journal:  J Leukoc Biol       Date:  2010-04-01       Impact factor: 4.962

3.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

4.  The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma.

Authors:  Anne Mueller; Jani O'rourke; Pauline Chu; Amanda Chu; Michael F Dixon; Donna M Bouley; Adrian Lee; Stanley Falkow
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

5.  Tumor-infiltrating T cells with similar antigen binding sites in different mucosa-associated lymphoid tissue type B cell lymphomas.

Authors:  Harald Seeberger; Constanze Knörr; Christian Mainhardt; Hans Konrad Müller-Hermelink; Axel Greiner
Journal:  Virchows Arch       Date:  2003-02-19       Impact factor: 4.064

6.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.

Authors:  Richard J Bende; Wilhelmina M Aarts; Robert G Riedl; Daphne de Jong; Steven T Pals; Carel J M van Noesel
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

Review 7.  Recent advances in understanding the biology of marginal zone lymphoma.

Authors:  Francesco Bertoni; Davide Rossi; Emanuele Zucca
Journal:  F1000Res       Date:  2018-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.